Transcatheter closure of patent foramen ovale following cryptogenic stroke: An updated meta-analysis of randomized controlled trials.

dc.contributor.author

Riaz, Haris

dc.contributor.author

Khan, Muhammad Shahzeb

dc.contributor.author

Schenone, Aldo L

dc.contributor.author

Waheed, Anam A

dc.contributor.author

Khan, Arooj Razzak

dc.contributor.author

Krasuski, Richard A

dc.date.accessioned

2019-02-01T14:44:45Z

dc.date.available

2019-02-01T14:44:45Z

dc.date.issued

2018-05

dc.date.updated

2019-02-01T14:44:44Z

dc.description.abstract

Transcatheter closure of patent foramen ovale (PFO) after cryptogenic stroke has long been a contentious issue. Herein, we pool aggregate data examining safety and efficacy of transcatheter closure of PFO compared with medical therapy following initial cryptogenic stroke.We searched for randomized clinical trials (RCT) that compared device closure with medical management and reported on subsequent stroke and adverse events. Stroke was considered as the primary efficacy endpoint, whereas bleeding and atrial fibrillation were considered primary safety endpoints. Data were pooled by the random effects model and I2 was used to assess heterogeneity.A total of 5 RCT investigating 3630 patients met inclusion criteria. Pooled analysis revealed that device closure compared to medical management was associated with a significant reduction in stroke (RR=0.3, 95% CI=0.02-0.57). There was, however, a significant increase in atrial arrhythmias with device therapy (RR=4.8, 95% CI=2.2-10.7). We found no increase in bleeding (RR=0.80, 95% CI=0.5-1.4), death (RR=0.76, 95% CI=0.3-1.99) or "any adverse events" (RR=1.02, 95% CI=0.85-1.23) with device therapy. Sub-group analysis revealed that device closure significantly reduced the incidence of the composite primary endpoint among patients who had moderate to large shunt sizes (RR=0.22, 95% CI=0.02-0.42).Transcatheter closure is associated with a significant reduction in the risk of stroke compared to medical management at the expense of an increased risk of atrial arrhythmias.

dc.identifier

S0002-8703(18)30021-8

dc.identifier.issn

0002-8703

dc.identifier.issn

1097-6744

dc.identifier.uri

https://hdl.handle.net/10161/17943

dc.language

eng

dc.publisher

Elsevier BV

dc.relation.ispartof

American heart journal

dc.relation.isversionof

10.1016/j.ahj.2018.01.008

dc.subject

Science & Technology

dc.subject

Life Sciences & Biomedicine

dc.subject

Cardiac & Cardiovascular Systems

dc.subject

Cardiovascular System & Cardiology

dc.subject

TRANSIENT ISCHEMIC ATTACK

dc.subject

MEDICAL THERAPY

dc.subject

PERCUTANEOUS CLOSURE

dc.subject

RECURRENT STROKE

dc.subject

DEVICE CLOSURE

dc.subject

PREVENTION

dc.title

Transcatheter closure of patent foramen ovale following cryptogenic stroke: An updated meta-analysis of randomized controlled trials.

dc.type

Journal article

duke.contributor.orcid

Krasuski, Richard A|0000-0003-3150-5215

pubs.begin-page

44

pubs.end-page

50

pubs.organisational-group

School of Medicine

pubs.organisational-group

Duke

pubs.organisational-group

Medicine, Cardiology

pubs.organisational-group

Medicine

pubs.organisational-group

Clinical Science Departments

pubs.publication-status

Published

pubs.volume

199

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PFO Meta Riaz.pdf
Size:
595.2 KB
Format:
Adobe Portable Document Format